KLF5 and cardiac hypertrophy: Because KLF5 induces ECM reorganization and can activate the promoter of PAI-1, which is an inhibitor of fibrin degradation, it contributes to accumulating ECM and leads to vascular wall thickening and cardiac hypertrophy [115].